Por favor, use este identificador para citar o enlazar este ítem:
https://repositorio.uca.edu.ar/handle/123456789/1609
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Srinivasan, Venkataramanujan | es |
dc.contributor.author | Brzezinski, Amnon | es |
dc.contributor.author | Pandi Perumal, Seithikurippu R. | es |
dc.contributor.author | Spence, David Warren | es |
dc.contributor.author | Cardinali, Daniel Pedro | es |
dc.contributor.author | Brown, Gregory M. | es |
dc.date.accessioned | 2019-05-02T14:01:04Z | - |
dc.date.available | 2019-05-02T14:01:04Z | - |
dc.date.issued | 2011 | - |
dc.identifier.citation | Srinivasan, V., et al. Melatonin agonists in primary insomnia and depression-associated insomnia : are they superior to sedative-hypnotics? [en línea]. Preprint de artículo publicado en Progress in Neuro-psychopharmacology & Biological Psychiatry. 2011, 35. doi:10.1016/j.pnpbp.2011.03.013. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/1609 | es |
dc.identifier.issn | 0278-5846 | - |
dc.identifier.uri | https://repositorio.uca.edu.ar/handle/123456789/1609 | - |
dc.description.abstract | Abstract: Current pharmacological treatment of insomnia involves the use of sedative-hypnotic benzodiazepine and non-benzodiazepine drugs. Although benzodiazepines improve sleep, their multiple adverse effects hamper their application. Adverse effects include impairment of memory and cognitive functions, nextday hangover and dependence. Non-benzodiazepines are effective for initiating sleep but are not as effective as benzodiazepines for improving sleep quality or efficiency. Furthermore, their prolonged use produces adverse effects similar to those observed with benzodiazepines. Inasmuch as insomnia may be associated with decreased nocturnal melatonin, administration of melatonin is a strategy that has been increasingly used for treating insomnia. Melatonin can be effective for improving sleep quality without the adverse effects associated with hypnotic-sedatives. Ramelteon, a synthetic analog of melatonin which has a longer half life and a stronger affinity for MT1 and MT2 melatonergic receptors, has been reportedly effective for initiating and improving sleep in both adult and elderly insomniacs without showing hangover, dependence, or cognitive impairment. Insomnia is also a major complaint among patients suffering from depressive disorders and is often aggravated by conventional antidepressants especially the specific serotonin reuptake inhibitors. The novel antidepressant agomelatine, a dual action agent with affinity for melatonin MT1 and MT2 receptors and 5-HT2c antagonistic properties, constitutes a new approach to the treatment of major depressive disorders. Agomelatine ameliorates the symptoms of depression and improves the quality and efficiency of sleep. Taken together, the evidence indicates that MT1 / MT2 receptor agonists like ramelteon or agomelatine may be valuable pharmacological tools for insomnia and for depression-associated insomnia. | es |
dc.format | application/pdf | es |
dc.language | eng | es |
dc.language.iso | eng | es |
dc.publisher | Elsevier | es |
dc.rights | Acceso Abierto | es |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-sa/4.0/ | es |
dc.source | Progress in Neuro-psychopharmacology & Biological Psychiatry. 2011, 35 | es |
dc.subject | MELATONINA | es |
dc.subject | AGONISTAS | es |
dc.subject | INSOMNIO | es |
dc.subject | DEPRESION | es |
dc.title | Melatonin agonists in primary insomnia and depression-associated insomnia : are they superior to sedative-hypnotics? | es |
dc.type | Artículo | es |
dc.identifier.doi | 10.1016/j.pnpbp.2011.03.013 | - |
uca.path | Facultad de Ciencias Médicas|Departamento de Docencia e Investigación | es |
uca.disciplina | MEDICINA | es |
uca.filename | /home/data-uca-generic/folder_generic/IIBiomedicas/melatonin-agonists-primary-insomnia-depression/metadata.xml | es |
uca.issnrd | 1 | es |
uca.affiliation | Fil: Srinivasan, Venkataramanujan. Sri Sathya Sai Medical Educational and Research Foundation; India | es |
uca.affiliation | Fil: Brzezinski, Amnon. The Hebrew University. Haddassah Medical Center. Department of Obstetrics and Gynecology; Israel | es |
uca.affiliation | Fil: Pandi Perumal, Seithikurippu R. Somnogen Inc; Estados Unidos | es |
uca.affiliation | Fil: Spence, David Warren. Canadian Sleep Institute; Canadá | es |
uca.affiliation | Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina. Facultad de Medicina. Departamento de Docencia e Investigación; Argentina | es |
uca.affiliation | Fil: Brown, Gregory M. Centre for Addiction and Mental Health; Canadá | es |
uca.version | submittedVersion | es |
item.grantfulltext | open | - |
item.fulltext | With Fulltext | - |
item.languageiso639-1 | en | - |
crisitem.author.dept | Consejo Nacional de Investigaciones Científicas y Técnicas | - |
crisitem.author.dept | Instituto de Investigaciones Biomédicas - BIOMED | - |
crisitem.author.dept | Facultad de Ciencias Médicas | - |
crisitem.author.orcid | 0000-0002-0813-9088 | - |
crisitem.author.parentorg | Facultad de Ciencias Médicas | - |
crisitem.author.parentorg | Pontificia Universidad Católica Argentina | - |
Aparece en las colecciones: | Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
melatonin-agonists-primary-insomnia-depression.pdf | 473,5 kB | Adobe PDF | Visualizar/Abrir |
Visualizaciones de página(s)
184
comprobado en 23-abr-2024
Descarga(s)
792
comprobado en 23-abr-2024
Google ScholarTM
Consultar
Altmetric
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons